Neoadjuvant and post-surgery immunotherapy for operable lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have operable NSCLC that can be surgically removed (stages IA3 to IIIA, with limited lymph node spread).
- Your scans show measurable cancer to track response (per RECIST).
- Your general health is good enough for treatment (ECOG 0 to 1).
- You have adequate blood/organ test results from samples taken within 14 days before starting.
- You can meet the trial’s birth control rules (and avoid pregnancy) during treatment and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.